Cidara Therapeutics reported positive Phase 2b results for its long-acting antiviral biologic CD-388, designed to prevent seasonal influenza in healthy adults aged 18 to 64. The single-dose treatment demonstrated significant efficacy in preventing laboratory-confirmed flu over 24 weeks and was well-tolerated across all doses. Following these promising outcomes, Cidara’s stock surged, and the company plans to engage with the FDA to discuss Phase 3 trial design. These developments position CD-388 as a potential alternative to traditional flu vaccines, addressing unmet needs in respiratory infection prevention.